Smart foot and ankle brace launches; ConforMIS ends recall investigation;

@FierceMedDev: ICYMI yesterday: Baxter, Boston Sci back TVA in $15M round to ease hemodialysis vascular access. Report | Follow @FierceMedDev

@VarunSaxena2: #AdvaMed15: Director of says local coverage decisions are varying by locality. Not all geographies reimburse Dx tests the same way. | Follow @VarunSaxena2

@EmilyWFierce: Sold on diabetes tech, Joslin tests mobile app for Type 1 patients. FiercePharmaMarketing story | Follow @EmilyWFierce

> Sensoria and Orthotics Holdings are launching a smart foot and ankle brace that's intended to not only help patients walk, but also enable physicians to monitor patient adherence, activity levels and gait parameters. More

> Customized joint implant maker ConforMIS ($CFMS) said that it has finished an investigation of excess moisture and ethylene glycol residue that led to a recall. It said that an independent lab round that the residue posed no significant health hazard. More

> Startup Sebacia has completed enrollment for its U.S. pivotal trial to treat severe acne. Patient follow-up will continue through December. More

> PE firm RoundTable Healthcare Partners has sold intraluminal catheter company Excelsior Medical to ICU Medical for almost $60 million. More

Biotech News

@FierceBiotech: Take the poll: Has the biotech boom come to an end? More | Follow @FierceBiotech

@JohnCFierce: Sold out the Fierce London biotech conference, which is cool. Thank you, U.K. More | Follow @JohnCFierce

> Quartet closes an up-sized A round with a novel approach to pain. News

> Aclaris limps out to a $55M IPO as biotech falters on Wall Street. Report

> Advaxis offers a tardy defense after FDA puts cancer vaccine on hold. Article

Pharma News

@FiercePharma: Something's got to give in India's pharma policy contradictions. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: AmerisourceBergen looks for compound interest with its $2.5B deal to buy PharMEDium. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Investors cheer as Arena forces out CEO and cofounder. More | Follow @CarlyHFierce

> U.K. cost gatekeeper says 'OK' to Merck's Keytruda for advanced skin cancer. Story

> Valeant hits back at price-hike critics amid national scrutiny. Article

> Two's company for PCSK9 meds as Praluent, Repatha both nab coverage from top PBM. More

Biotech Research News

> Rutgers researchers make headway with an HDAC inhibitor for Alzheimer's. More

> Alzheimer's: Investigators spotlight a pathway for amyloid beta clearance. Report

> Penn team shines a light on blood disorder. Item

> UCSC team reveals key structural component in telomerase enzyme. Story

> NIH researchers' new mouse model points to a gene therapy for eye disease. Article

Diagnostics News

> Myriad inks coverage deal for prostate cancer test. Item

> Invitae doubles genetic testing menu with cancer, neuromuscular offerings. Report

> Cancer Genetics makes strides in $14M deal for Response Genetics. More

> Invitae doubles genetic testing menu with cancer, neuromuscular offerings. Article

> Illumina expands in China with cancer Dx deal. Story

Pharma Marketing News

> Can Daklinza profit from a set of niche hep C uses? BMS may soon find out. Item

> Bristol-Myers shells out $14.7M in China bribery settlement. More

> British docs weigh in on pharma, and it's no better than most U.S. opinions. Report

> The data difference? Publicis adds data practice to sharpen healthcare media buying and planning. Story

> Glaxo OTC chief: When it comes to consumer health, pharma has the edge. Article

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.